Comparison of the clinical outcome of instant single intravesical instillation of pirarubicin and multiple instillations after TUR-Bt for preventing recurrence of non muscle-invasive bladder cancer
10.3781/j.issn.1000-7431.2008.10.017
- Author:
Huan XU
1
Author Information
1. Department of Urology
- Publication Type:Journal Article
- Keywords:
Bladder neoplasms;
Chemotherapy, cancer, regional perfusion;
Follow studies;
Pirarubicin
- From:
Tumor
2008;28(10):889-891
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the effectiveness and security of instant single intravesical instillation of pirarubicin and multiple instillations at two weeks after transurethral resection of bladder tumor (TUR-Bt) for prevention of non muscle-invasive bladder cancer recurrence. Methods: We recruited 162 non muscle-invasive bladder cancer patients from Mar 2003 to Jun 2005. They were randomly divided into 2 groups: 80 cases received instant single intravesical instillation of pirarubicin post operation (group RG) and 82 cases were given multiple intravesical perfusions of pirarubicin regularly after two weeks of operation (group CG). The recurrence rates and side effects between the two groups were compared. Results: Totally six patients lost follow-up. The two groups both had 78 valid follow-up cases. The follow-up period was 24 to 48 months. The recurrence rate was 25.6% (20/78) in group RG, and 17.9% (14/78) in group CG. There was no significant difference between the two groups. The recurrence rates of G2 and G3 tumor were 42.5% (17/40) in group RG, and 20.9% (9/43) in group CG. The recurrence rate of group CG was lower than that in group RG in subset tumor at higher grade (G2 and G3). Conclusion: The total effectiveness of instant single intravesical instillation of chemotherapy is similar to multiple instillations of chemotherapy after two weeks of TUR-Bt for preventing the recurrence of non muscle-invasive bladder cancer. But multiple instillations can better decrease the recurrence of non muscle-invasive bladder cancer at higher pathological grade (G2 and G3).
